BioNTech's cancer drug meets primary endpoint in Phase 2 trial
Go back to BioNTech's cancer drug meets primary endpoint in Phase 2 trial| (NASDAQ: BNTX) | Delayed: 100.87 +2.87 (2.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.00 | 52 Week High | $ | |||
| Open | $98.00 | 52 Week Low | $ | |||
| Day High | $102.23 | P/E | N/A | |||
| Day Low | $97.46 | EPS | $ | |||
| Volume | 1,050,808 | |||||
